NIH trial testing hyperimmune intravenous immunoglobulin and remdesivir to treat COVID-19

(NIH/National Institute of Allergy and Infectious Diseases) A clinical trial to test the safety, tolerability and efficacy of a combination treatment regimen for COVID-19 consisting of the antiviral remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2 has begun. The study is taking place in hospitalized adults with COVID-19 in the United States, Mexico and 16 other countries on five continents. NIAID is sponsoring and funding the Phase 3 trial, called Inpatient Treatment with Anti-Coronavirus Immunoglobulin, or ITAC.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news